Company intelligence / Profile preview

INmune Bio Inc.

Boca Raton, Florida, United Statesinmunebio.com ↗

Ownership: Public · INMB
Employees: ~50
Development stage: Other

Overview

Currently conducting multiple clinical trials including a Phase 2 trial for Alzheimer's disease with 208 patients (overenrolled) with topline cognitive results expected in Q2 2025[10]. Phase I/II trial for INKmune in metastatic castration-resistant prostate cancer has completed Phase I portion with no safety issues and is now enrolling Phase II high dose cohort[6][9]. CORDStrom showed promising results in a Phase 2 randomized trial for recessive dystrophic epidermolysis bullosa[8].

Therapeutic areas: DermatologyOncologyPsychiatryNeurology
Modalities: Cell therapyDominant-Negative TNF technology
Industry: Biotech

Drug pipeline

5 assets

INKmune

4 more assets in the full pipeline.

Partnerships

Cell and Gene Therapy Catapult

Financials

Market cap: $32.6M
Total revenue: $50K
Enterprise value: $17.5M

Beyond the preview

Go deeper on INmune Bio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INmune Bio Inc..